ArticleFrontiers in oncology2020
Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.Blood advances · 2021Trial
- Review
- Article
- Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.Frontiers in immunology · 2024Article
- [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Article
- Juvenile myelomonocytic leukemia presenting in an infant with a subdural hematoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- Treatment advances for pediatric and adult onset neoplasms with monocytosis.Current hematologic malignancy reports · 2021Review
- Editorial: Novel Drugs Targeting the Microenvironment and the Epigenetic Changes in Hematopoietic Malignancies.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.